Qiming Star | Tianchen Biotech Raises Over 200 Million Yuan in Series C, Co-Led by Qiming Venture Partners
TianChen Bio is committed to setting the industry benchmark in allergic diseases and complement-mediated diseases, continuously driving treatment innovation to deliver breakthrough therapies with greater clinical value and accessibility for patients worldwide.









